Orexigen Therapeutics, Inc. at BIO & CEO Investor Conference (Replay)
02/14/17 at 10:00 a.m. ET
Orexigen Therapeutics, Inc. at The LEERINK Partners 6th Annual Global Healthcare Conference (Replay)
02/16/17 at 11:30 a.m. ET
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen’s first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolonged relMore >>
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.